Topic starter
09/06/2026 11:12 pm
TL;DR: Life sciences metadata is the chain of custody that regulators use to judge whether trial data is attributable, auditable and defensible, according to Collibra, and weak lineage can unravel even strong efficacy results. Metadata governance is not a documentation layer; it is the control surface that turns clinical data into evidence.
Editorial analysis by NHI Mgmt Group, based on content published by Collibra: “Clinical data is only as credible as its context”.
Key questions
Q: How should life sciences teams govern metadata for regulated submissions?
A: They should treat metadata as regulated evidence, not administrative detail.
Q: What breaks when clinical data lacks strong metadata governance?
A: Reviewability breaks first, followed by defensibility.
Q: How can teams tell whether metadata governance is actually working?
A: Look for whether records can be traced end to end without manual reconstruction.
Practitioner guidance
- Define regulated metadata fields Standardise the minimum metadata set for clinical records, including provenance, timestamp, system identifier, and change history, so every dataset carries the evidence regulators expect.
- Automate metadata capture at source Capture audit trail, lineage, and ownership data automatically inside the systems where clinical and lab records are created rather than relying on manual transcription.
- Assign named stewardship for metadata quality Make one function responsible for metadata completeness, consistency, and review readiness across studies and submissions, with clear escalation when records are missing context.
Bottom line: Metadata in life sciences is a governance control because it proves who created a record, when it changed, and whether it remains defensible.
Explore further
View Full Forum → | NHI Foundation Course → | Our Services → | Read the full analysis →
This topic was modified 23 hours ago by NHI Mgmt Group
10/06/2026 1:28 am
Metadata governance is the control plane for regulated evidence. In life sciences, the question is not whether the dataset contains the right numbers but whether the organisation can prove where those numbers came from and who touched them. FDA 21 CFR Part 11 and ALCOA+ both reflect the same underlying governance requirement: data must remain attributable across its full lifecycle. Practitioners should treat metadata as the proof layer for regulated identity and access, not as an administrative afterthought.
A few things that frame the scale:
- Only 5.7% of organisations have full visibility into their service accounts, according to Ultimate Guide to NHIs , Key Research and Survey Results.
- 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools.
A question worth separating out:
Q: Who should own metadata governance in regulated life sciences programmes?
A: Ownership should sit with a named business steward and a technical steward, because metadata is both operational and evidentiary. The business owner defines what must be proven, while the technical owner ensures those fields are captured, protected and auditable across the lifecycle.
👉 Read our full editorial: Metadata governance in life sciences is now a regulatory control
11/06/2026 12:32 am
Metadata governance is the control plane for regulated evidence. In life sciences, the question is not whether the dataset contains the right numbers but whether the organisation can prove where those numbers came from and who touched them. FDA 21 CFR Part 11 and ALCOA+ both reflect the same underlying governance requirement: data must remain attributable across its full lifecycle. Practitioners should treat metadata as the proof layer for regulated identity and access, not as an administrative afterthought.
A few things that frame the scale:
- Only 5.7% of organisations have full visibility into their service accounts, according to Ultimate Guide to NHIs , Key Research and Survey Results.
- 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools.
A question worth separating out:
Q: Who should own metadata governance in regulated life sciences programmes?
A: Ownership should sit with a named business steward and a technical steward, because metadata is both operational and evidentiary. The business owner defines what must be proven, while the technical owner ensures those fields are captured, protected and auditable across the lifecycle.
👉 Read our full editorial: Metadata governance in life sciences is now a regulatory control
12/06/2026 2:05 am
Metadata governance has become an evidentiary control, not a data-management accessory. In regulated life sciences, the question is no longer whether the dataset exists but whether the surrounding metadata can prove provenance, integrity, and handling. That shifts metadata from a passive record-keeping function to a governance requirement that stands beside the clinical data itself. Practitioners should treat metadata as part of the regulated evidence package.
A question worth separating out:
Q: What is the difference between data quality and metadata governance in life sciences?
A: Data quality asks whether the result is accurate, complete, and usable. Metadata governance asks whether the organisation can prove where that result came from, who handled it, when it changed, and whether the record remained trustworthy throughout its lifecycle.
👉 Read our full editorial: Metadata governance in life sciences is now a regulatory control
This post was modified 23 hours ago by NHI Mgmt Group